COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: The Company is a newly established investing company incorporated on 11 June 2020 in England and Wales. The Board will seek to provide investors in the Company with exposure to a portfolio of investments concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US. The Company will invest in early and later-stage Life Sciences businesses. Investments are expected to be mainly in the form of equity and equity-related instruments, including convertible debt instruments in certain circumstances.